Inclusion Criteria:
* Males or females ≥ 50 and ≤ 85 years at the time of signing the ICF;
* Active macular choroidal neovascularization (MNV) secondary to nAMD in the study eye;
* Sentinel (1st) subject for each dose cohort must have a BCVA ≤ 20/63 and ≥ 20/400 (≤63 and ≥ 19 ETDRS letters) in the study eye. Following the sentinel subject evaluation, the rest of the subjects in the dose cohort must have a BCVA between ≤ 20/40 and ≥ 20/400 (≤ 73 and ≥ 19 ETDRS letters) in the study eye.
* Able to perform visual acuity and retinal function tests and able and willing to comply with study procedures for this clinical trial.
Exclusion Criteria:
* Retinal or subretinal hemorrhage, scarring, or fibrosis of greater than 50% of the total lesion in the study eye;
* Other ocular diseases that may affect central vision in the study eye;
* Any other cause of CNV than nAMD in the study eye
* Uncontrolled glaucoma in the study eye;
* History or presence of corneal transplant or corneal dystrophy in the study eye;
* History of other intraocular surgery in the study eye within 3 months prior to baseline;
* Prior gene therapy or oligonucleotide therapy;
* Other conditions judged by the investigator as inappropriate for the study.
View Inclusion and Exclusion Criteria at ClinicalTrials.gov